The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved]

The prevalence of heart failure is expected to increase almost 50% in the next 15 years because of aging of the general population, an increased frequency of comorbidities, and an improved survival following cardiac events. Conventional treatments for heart failure have remained largely static over...

Full description

Bibliographic Details
Main Authors: Michael S. Kapiloff, Craig A. Emter
Format: Article
Language:English
Published: F1000 Research Ltd 2016-01-01
Series:F1000Research
Subjects:
Online Access:http://f1000research.com/articles/5-72/v1
id doaj-2c72ddc31efd49d9aa026eb8bec579a8
record_format Article
spelling doaj-2c72ddc31efd49d9aa026eb8bec579a82020-11-25T04:00:13ZengF1000 Research LtdF1000Research2046-14022016-01-01510.12688/f1000research.7278.17843The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved]Michael S. Kapiloff0Craig A. Emter1Cardiac Signal Transduction and Cellular Biology Laboratory, Interdisciplinary Stem Cell Institute, Departments of Pediatrics and Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USADepartment of Biomedical Sciences, University of Missouri-Columbia, Columbia, MO, USAThe prevalence of heart failure is expected to increase almost 50% in the next 15 years because of aging of the general population, an increased frequency of comorbidities, and an improved survival following cardiac events. Conventional treatments for heart failure have remained largely static over the past 20 years, illustrating the pressing need for the discovery of novel therapeutic agents for this patient population. Given the heterogeneous nature of heart failure, it is important to specifically define the cellular mechanisms in the heart that drive the patient’s symptoms, particularly when considering new treatment strategies. This report highlights the latest research efforts, as well as the possible pitfalls, in cardiac disease translational research and discusses future questions and considerations needed to advance the development of new heart failure therapies. In particular, we discuss cardiac remodeling and the translation of animal work to humans and how advancements in our understanding of these concepts relative to disease are central to new discoveries that can improve cardiovascular health.http://f1000research.com/articles/5-72/v1Cardiovascular PharmacologyDrug Discovery & DesignHealth Systems & Services ResearchHeart FailureHypertensionMolecular Pharmacology
collection DOAJ
language English
format Article
sources DOAJ
author Michael S. Kapiloff
Craig A. Emter
spellingShingle Michael S. Kapiloff
Craig A. Emter
The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved]
F1000Research
Cardiovascular Pharmacology
Drug Discovery & Design
Health Systems & Services Research
Heart Failure
Hypertension
Molecular Pharmacology
author_facet Michael S. Kapiloff
Craig A. Emter
author_sort Michael S. Kapiloff
title The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved]
title_short The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved]
title_full The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved]
title_fullStr The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved]
title_full_unstemmed The cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved]
title_sort cardiac enigma: current conundrums in heart failure research [version 1; referees: 3 approved]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2016-01-01
description The prevalence of heart failure is expected to increase almost 50% in the next 15 years because of aging of the general population, an increased frequency of comorbidities, and an improved survival following cardiac events. Conventional treatments for heart failure have remained largely static over the past 20 years, illustrating the pressing need for the discovery of novel therapeutic agents for this patient population. Given the heterogeneous nature of heart failure, it is important to specifically define the cellular mechanisms in the heart that drive the patient’s symptoms, particularly when considering new treatment strategies. This report highlights the latest research efforts, as well as the possible pitfalls, in cardiac disease translational research and discusses future questions and considerations needed to advance the development of new heart failure therapies. In particular, we discuss cardiac remodeling and the translation of animal work to humans and how advancements in our understanding of these concepts relative to disease are central to new discoveries that can improve cardiovascular health.
topic Cardiovascular Pharmacology
Drug Discovery & Design
Health Systems & Services Research
Heart Failure
Hypertension
Molecular Pharmacology
url http://f1000research.com/articles/5-72/v1
work_keys_str_mv AT michaelskapiloff thecardiacenigmacurrentconundrumsinheartfailureresearchversion1referees3approved
AT craigaemter thecardiacenigmacurrentconundrumsinheartfailureresearchversion1referees3approved
AT michaelskapiloff cardiacenigmacurrentconundrumsinheartfailureresearchversion1referees3approved
AT craigaemter cardiacenigmacurrentconundrumsinheartfailureresearchversion1referees3approved
_version_ 1724451823725576192